Knee injections with or without a PEA supplement for knee pain from joint wear
Compares knee injections of adelmidrol and hyaluronic acid, with or without PEA, in knee arthritis.
Plain-language title generated from the registry record
Registry title: Intra-Articular Adelmidrol 2%/Hyaluronic Acid 1% With or Without m/umPEA, in Knee Pain Due to Joint Degeneration.
Key facts
- Where
- Verona, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with knee pain from worn knee joints, due to osteoarthritis or rheumatoid arthritis.
- Age
- 40 years or older
- Sex
- Men and women
- Disease stage
- Knee joint wear in one or both knees from osteoarthritis or rheumatoid arthritis, Kellgren-Lawrence grade II-III. Knee pain for at least 6 months. Baseline WOMAC score of 20 or more.
- Earlier treatment
- People with rheumatoid arthritis need drug therapy that has been stable for at least 3 months. People must not have taken palmitoylethanolamide before.
Main reasons for not taking part
- Severe progressive diseases that affect the whole body
- Knee injections within the last 3 months
- Knee surgery within the last 6 months
- Chronic NSAID therapy
- Pregnancy or breastfeeding
Read by machine on 13 November 2026.
Where in Italy
- Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyContact: Enrico PolatiNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Universita di Verona
- Trial code
- NCT07680101
- Record updated
- 2 July 2026
- Original description
Degenerative knee joint diseases are characterized by chronic pain, inflammation, and functional impairment. In these conditions, mast cell density in the synovial membrane is increased, resulting in an excessive release of biological mediators involved in key mechanisms of neuroinflammation and in hyaluronic acid depolymerisation. Adelmidrol acts as a preventive antioxidant due to its radical scavenging activity, thus protecting hyaluronic acid from oxidative degradation and reducing mast cell degranulation. Furthermore, a reduction in endogenous Palmitoylethanolamide (PEA) levels also contributes to joint neuroinflammation and disease progression; therefore, its exogenous supplementation may represent a valuable supportive strategy.Read full original descriptionShow less
Efficacy of Intra-articular Treatment With Adelmidrol 2% / Hyaluronic Acid 1%, With or Without m/umPEA, in Knee Pain Due to Joint Degeneration: a Bicentric, Prospective, Randomized Study.
Degenerative knee joint diseases are characterized by chronic pain, inflammation, and functional impairment. In these conditions, mast cell density in the synovial membrane is increased, resulting in an excessive release of biological mediators involved in key mechanisms of neuroinflammation and in hyaluronic acid depolymerisation. Adelmidrol acts as a preventive antioxidant due to its radical scavenging activity, thus protecting hyaluronic acid from oxidative degradation and reducing mast cell degranulation. Furthermore, a reduction in endogenous Palmitoylethanolamide (PEA) levels also contributes to joint neuroinflammation and disease progression; therefore, its exogenous supplementation may represent a valuable supportive strategy.
The objective of this clinical investigation is to compare the efficacy of intra-articular adelmidrol/hyaluronic acid treatment alone versus the same intra-articular treatment combined with oral micronized /ultramicronized PEA in patients with knee joint degeneration due to osteoarthritis or rheumatoid arthritis.
Inclusion: Age ≥ 40 years; Male or female; Diagnosis of unilateral or bilateral knee joint degeneration due to osteoarthritis or rheumatoid arthritis, Kellgren-Lawrence grade II-III; Duration of knee pain ≥ 6 months; Baseline WOMAC score ≥ 20; Drug therapy stabilized for at least 3 months in the case of patients with rheumatoid arthritis; Naïve to palmitoylethanolamide treatment; Signed informed consent.
Exclusion: Intra-articular knee injections within 3 months prior to enrollment; Knee surgery within 6 months prior to enrollment; Systemic treatment with chondroprotectors within 1 month prior to enrollment; Systemic corticosteroid treatment within 1 month prior to enrollment; Chronic Non-Steroidal Anti-Inflammatory Drugs (NSAID) therapy; Severe progressive systemic diseases; Known hypersensitivity to study treatments; Contraindications to intra-articular knee injections; Pregnancy or breastfeeding.